Prostate cancer early detection, version 1.2014: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 9, 2014, Pages 1211-1219

  Carroll, Peter R ^a   Parsons, J Kellogg ^b   Andriole, Gerald ^c   Bahnson, Robert R ^d   Barocas, Daniel A ^e   Catalona, William J ^f   Dahl, Douglas M ^g   Davis, John W ^h   Epstein, Jonathan I ⁱ   Etzioni, Ruth B ^j   Giri, Veda N ^k   Hemstreet, George P ^l   Kawachi, Mark H ^m   Lange, Paul H ^j   Loughlin, Kevin R ⁿ   Lowrance, William ^o   Maroni, Paul ^p   Mohler, James ^q   Morgan, Todd M ^r   Nadler, Robert B ^f   Poch, Michael ^s   Scales, Chuck ^t   Shanefelt, Terrence M ^u   Vickers, Andrew J ^v   Wake, Robert ^w   Shead, Dorothy A ^x   Ho, Maria ^x   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j SEATTLE CANCER CARE ALLIANCE   (United States)

^k FOX CHASE CANCER CENTER   (United States)

^l NEBRASKA MEDICAL CENTER   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ Dana Farber   (United States)

^o UNIVERSITY OF UTAH   (United States)

^p University of Colorado Cancer Center   (United States)

^q ROSWELL PARK CANCER INSTITUTE   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t DUKE CANCER INSTITUTE   (United States)

^u UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^x National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

AGE; ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTINUING EDUCATION; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EUROPEAN; FALSE POSITIVE RESULT; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; HUMAN; MEDICAL RESEARCH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATE HEALTH INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; TUMOR BIOPSY; HEALTH SURVEY; MALE; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS;

AGE FACTORS; EARLY DETECTION OF CANCER; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907288188     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0120     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Surveillance, Epidemiology, and Ends Results Program. Fast Stats. Available at: http://seer.cancer.gov/faststats/selections.php. Accessed March 11, 2014.
3. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-605.
4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
6. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen - based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013;158:145-153.
7. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
8. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-132.
9. Andriole GL. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Recent Results Cancer Res 2014;202:53-57.
10. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011;29:355-361.
11. Bach PB, Vickers AJ. Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? J Clin Oncol 2011;29:e387.
12. Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009;169:1603-1610.
13. Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210-1219.
14. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
15. Capitanio U, Perrotte P, Zini L, et al. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. Urology 2009;73:1323-1327.
16. Chun FK, Hutterer GC, Perrotte P, et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 2007;100:37-41.
17. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008;6:6.
18. Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009;182:2242-2248.
19. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235-241.
20. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010;341:c4521.
21. Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly - when to stop? J Urol 2009;181:1606-1614.
22. van Leeuwen PJ, Roobol MJ, Kranse R, et al. Towards an optimal interval for prostate cancer screening. Eur Urol 2012;61:171-176.
23. Nam RK, Kattan MW, Chin JL, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol 2011;29:2959-2964.
24. Nam RK, Toi A, Klotz LH, et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007;25:3582-3588.
25. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-534.
26. Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
27. Glass AS, Cary KC, Cooperberg MR. Risk-based prostate cancer screening: who and how? Curr Urol Rep 2013;14:192-198.
28. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527.
29. Partin AW, Brawer MK, Subong EN, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998;1:197-203.
30. Bradley LA, Palomaki GE, Gutman S, et al. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013;190:389-398.
31. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729-739.
32. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112:313-321.
33. Loeb S. Prostate cancer: Prostate Health Index - improving screening in men with family history. Nat Rev Urol 2013;10:497-498.
34. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]proprostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650-1655.
35. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255-261.